Company Profile: Steril-Gene Life Sciences Private Limited
Background
Steril-Gene Life Sciences Private Limited, established in 2007, is a pharmaceutical services company specializing in development, manufacturing, technology transfers, and site transfers for pharmaceutical firms globally. Located in Puducherry, India, the company operates a state-of-the-art facility built to US FDA standards, covering approximately 81,000 square meters. This facility has been operational since 2010 and is designed to meet global regulatory and cGMP norms.
The company's mission is to serve as a one-stop shop for manufacturing high-quality medicines, providing end-to-end solutions that enable pharmaceutical companies worldwide to focus on delivering medicines to patients. Its vision is to be a global manufacturing company offering value-added solutions to pharmaceutical companies.
Key Strategic Focus
Steril-Gene's strategic focus encompasses:
- Comprehensive Service Offering: Providing contract research and manufacturing services, contract manufacturing services, technology transfer services, site transfers, and regulatory services.
- Diverse Manufacturing Portfolio: Producing a wide range of pharmaceutical preparations, including liquid injectables, lyophilized injectable vials, prefilled syringes, ophthalmic vials, tablets, hard gelatin capsules, and soft gelatin capsules.
- Specialized Capabilities: Manufacturing hormonal, potent, and general category drugs.
- Global Market Reach: Exporting finished products to Europe, Africa, Asia, CIS, and Central and Latin American countries.
Financials and Funding
As of March 31, 2023, Steril-Gene Life Sciences reported:
- Authorized Share Capital: INR 216.00 crore
- Paid-up Capital: INR 212.64 crore
- Operating Revenue: Between INR 100 crore and INR 500 crore
- EBITDA Growth: Increased by 34.27% over the previous year
- Net Worth Growth: Increased by 522.96%
The company has active open charges totaling INR 339.75 crore, primarily with HDFC Bank Limited.
Pipeline Development
Steril-Gene's manufacturing portfolio includes:
- Injectables: Ampoules (1ml to 10ml), vials (1ml to 100ml), prefilled syringes, ophthalmic vials
- Oral Dosage Forms: Softgel capsules, tablets, hard gelatin capsules, sachets
The company is equipped to manufacture hormonal, potent, and general category drugs, adhering to global regulatory standards.
Technological Platform and Innovation
Steril-Gene's facility is divided into four separate manufacturing units based on drug categories, with a built-up area of approximately 40,000 square meters. The plant is constructed to meet global regulatory and FDA requirements, adhering to current Good Manufacturing Practice (cGMP) norms.
Leadership Team
The leadership team includes:
- Sulaiman Abdulhai Mohammed: Managing Director since 2007
- Zenaida Dizon Balajadia: Director since 2009
- Lloyd Dizon Balajadia: Director since 2009
- Dennis Dizon Balajadia: Director since 2009
- Dick Dizon Balajadia: Director since 2009
- Maximo Ponce Balajadia: Director since 2009
- Alagappan: Director since 2013
- Kannappan Nagappan: Director since 2013
- Chanpreet Singh Anand: Whole-time Director since 2015
- Vijay Balakumar: Director since 2023
- Manohar Srivignesh: Director since 2023
- Pabitti Manjulatha: Company Secretary since 2018
Leadership Changes
Recent appointments include:
- Vijay Balakumar: Appointed as Director on December 14, 2023
- Manohar Srivignesh: Appointed as Director on December 14, 2023
Competitor Profile
Market Insights and Dynamics
The pharmaceutical contract manufacturing market is experiencing significant growth, driven by increasing demand for generic drugs, outsourcing of manufacturing activities, and stringent regulatory requirements. Companies like Steril-Gene are well-positioned to capitalize on these trends by offering comprehensive manufacturing and development services.
Competitor Analysis
Key competitors in the pharmaceutical contract manufacturing sector include:
- Med Manor Organics: Specializes in contract manufacturing of pharmaceutical formulations.
- Torque Pharmaceuticals: Offers a wide range of pharmaceutical products and contract manufacturing services.
- Walter Bushnell: Engages in the manufacturing and marketing of pharmaceutical formulations.
- VWR International: Provides laboratory supplies and services, including pharmaceutical manufacturing support.
- Ferring Pharmaceuticals: Focuses on research, development, and manufacturing of pharmaceutical products.
These companies compete in areas such as product range, manufacturing capabilities, regulatory compliance, and global market reach.
Strategic Collaborations and Partnerships
Steril-Gene is a joint venture between The Madras Pharmaceuticals, India, and Lloyd Laboratories, Philippines. Both parent companies have over 40 years of experience in the pharmaceutical industry, bringing extensive expertise and market knowledge to the venture.
Operational Insights
Steril-Gene's strategic considerations include:
- Regulatory Compliance: Maintaining facilities that meet global regulatory standards, including US FDA requirements.
- Diversified Product Portfolio: Offering a wide range of dosage forms and specialized drug categories.
- Global Market Penetration: Exporting products to multiple international markets, enhancing global presence.
Strategic Opportunities and Future Directions
Steril-Gene aims to:
- Expand Service Offerings: Enhance contract research and manufacturing services to meet evolving client needs.
- Strengthen Global Partnerships: Forge new alliances to expand market reach and capabilities.
- Invest in Innovation: Develop proprietary technologies and methodologies to maintain a competitive edge.
Contact Information
- Website: steril-gene.com
- Headquarters: Chennai, Tamil Nadu, India
For more information, visit the company's official website.
